Get the Stockscreener App
467.35
1.35%
6.21
After Hours:
466.60
-0.75
-0.16%
Vertex Pharmaceuticals Inc stock is traded at $467.35, with a volume of 1.51M.
It is up +1.35% in the last 24 hours and up +1.53% over the past month.
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
See More
Previous Close:
$461.14
Open:
$463.74
24h Volume:
1.51M
Relative Volume:
1.08
Market Cap:
$118.58B
Revenue:
$11.74B
Net Income/Loss:
$3.68B
P/E Ratio:
32.94
EPS:
14.1888
Net Cash Flow:
$3.34B
1W Performance:
+6.48%
1M Performance:
+1.53%
6M Performance:
-0.59%
1Y Performance:
+9.19%
1-Day Range:
$458.31
$472.58
1-Week Range:
$429.00
$472.58
52-Week Range:
$362.50
$519.68
Vertex Pharmaceuticals Inc Stock (VRTX) Company Profile
Name
Vertex Pharmaceuticals Inc
Sector
Industry
Phone
(617) 341-6393
Address
50 NORTHERN AVENUE, BOSTON, MA
Compare VRTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VRTX
Vertex Pharmaceuticals Inc
|
467.35 | 117.00B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.51 | 78.75B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
827.02 | 50.52B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
370.00 | 48.28B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.81 | 37.81B | 4.98B | 69.59M | 525.67M | 0.5197 |
Vertex Pharmaceuticals Inc Stock (VRTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-12-26 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Jan-07-26 | Resumed | UBS | Buy |
| Jan-06-26 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Dec-03-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Sep-25-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Sep-03-25 | Initiated | Raymond James | Mkt Perform |
| Aug-06-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| May-07-25 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| May-06-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Apr-22-25 | Resumed | Cantor Fitzgerald | Overweight |
| Feb-12-25 | Upgrade | Canaccord Genuity | Sell → Hold |
| Feb-11-25 | Upgrade | Canaccord Genuity | Sell → Hold |
| Jan-30-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Dec-20-24 | Reiterated | H.C. Wainwright | Buy |
| Dec-19-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Dec-09-24 | Upgrade | Jefferies | Hold → Buy |
| Nov-14-24 | Initiated | Citigroup | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Perform |
| Oct-10-24 | Resumed | Raymond James | Mkt Perform |
| Aug-05-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Jun-27-24 | Initiated | Redburn Atlantic | Buy |
| Apr-11-24 | Upgrade | Evercore ISI | In-line → Outperform |
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Feb-06-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Feb-02-24 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Jan-31-24 | Downgrade | Maxim Group | Buy → Hold |
| Jan-31-24 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Jan-24-24 | Downgrade | Canaccord Genuity | Hold → Sell |
| Dec-14-23 | Reiterated | RBC Capital Mkts | Sector Perform |
| May-30-23 | Initiated | William Blair | Outperform |
| May-04-23 | Resumed | Piper Sandler | Overweight |
| Mar-21-23 | Initiated | Bernstein | Outperform |
| Jan-18-23 | Initiated | Canaccord Genuity | Hold |
| Jan-17-23 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Dec-19-22 | Downgrade | Jefferies | Buy → Hold |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-01-22 | Upgrade | Maxim Group | Hold → Buy |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| May-06-22 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-03-22 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Feb-03-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jan-27-22 | Reiterated | JP Morgan | Overweight |
| Jan-27-22 | Reiterated | Morgan Stanley | Underweight |
| Jan-27-22 | Reiterated | RBC Capital Mkts | Outperform |
| Jan-27-22 | Reiterated | Stifel | Hold |
| Jan-27-22 | Reiterated | Wolfe Research | Outperform |
| Jan-20-22 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Dec-09-21 | Initiated | Wells Fargo | Overweight |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Nov-19-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Sep-09-21 | Downgrade | Stifel | Buy → Hold |
| Sep-07-21 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jul-20-21 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jul-19-21 | Resumed | Wolfe Research | Outperform |
| Jul-01-21 | Initiated | Raymond James | Mkt Perform |
| Jun-11-21 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Feb-23-21 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Feb-02-21 | Reiterated | H.C. Wainwright | Buy |
| Dec-30-20 | Initiated | Daiwa Securities | Outperform |
| Nov-30-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-20-20 | Initiated | Bernstein | Outperform |
| Oct-28-20 | Initiated | UBS | Buy |
| Jul-31-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-08-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-30-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-28-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Jan-31-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Nov-19-19 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| Sep-03-19 | Upgrade | Goldman | Neutral → Buy |
| Aug-01-19 | Downgrade | Needham | Buy → Hold |
| May-23-19 | Resumed | Citigroup | Buy |
| May-21-19 | Initiated | Credit Suisse | Outperform |
| Apr-12-19 | Initiated | Evercore ISI | In-line |
| Mar-26-19 | Upgrade | William Blair | Mkt Perform → Outperform |
| Mar-19-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Feb-06-19 | Downgrade | Maxim Group | Buy → Hold |
View All
Vertex Pharmaceuticals Inc Stock (VRTX) Latest News
FDA Grants Orphan Status to Vertex Pharmaceuticals' (VRTX) Treat - GuruFocus
Vertex Pharmaceuticals (VRTX) Upgraded on Strong Cystic Fibrosis Franchise - GuruFocus
Final Trades: Vertex Pharma, Kimberly-Clark, S&P Global and Exxon Mobil - CNBC
Vertex Pharma Stock Is Quietly Going Off – But Is It Actually Worth Your Money? - AD HOC NEWS
RBC Capital Upgrades Vertex Pharmaceuticals (VRTX) Rating to 'Ou - GuruFocus
Vertex Pharma upgraded at RBC Capital Markets (VRTX:NASDAQ) - Seeking Alpha
Vertex Pharmaceuticals (NASDAQ:VRTX) Upgraded to Outperform at Royal Bank Of Canada - MarketBeat
Boston Common Asset Management LLC Sells 5,164 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Neuropathic Pain Market to Reach US$ 18.45 Billion by 2033 at 8.9% - openPR.com
Is Bullish CF Analyst Sentiment Reframing the Pipeline Risk Narrative for Vertex Pharmaceuticals (VRTX)? - Yahoo Finance
Vertex Pharma wins EU backing to expand label for Kaftrio cystic fibrosis drug - MSN
Vertex Pharmaceuticals Incorporated $VRTX Shares Sold by Wealth Enhancement Advisory Services LLC - MarketBeat
Rakuten Investment Management Inc. Makes New $94.96 Million Investment in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals Incorporated $VRTX Stake Boosted by Universal Beteiligungs und Servicegesellschaft mbH - MarketBeat
Migdal Insurance & Financial Holdings Ltd. Makes New Investment in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals Incorporated $VRTX Shares Sold by Bailard Inc. - MarketBeat
Reflecting On Therapeutics Stocks’ Q3 Earnings: Vertex Pharmaceuticals (NASDAQ:VRTX) - Yahoo Finance
Vertex to Announce Fourth Quarter and Full Year 2025 Financial Results on February 12th - Business Wire
Americana Partners LLC Buys 12,134 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Allstate Corp Makes New $3.64 Million Investment in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Unpacking Q3 Earnings: Vertex Pharmaceuticals (NASDAQ:VRTX) In The Context Of Other Therapeutics Stocks - Barchart.com
Bernstein Names Vertex (VRTX) a "Top Biotech Pick" for 2026 Following Upgrade to Outperform - Yahoo Finance
Nippon Life Global Investors Americas Inc. Makes New $1.11 Million Investment in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Stenger Family Office LLC Takes Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
QRG Capital Management Inc. Has $6.20 Million Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
The Truth About Vertex Pharmaceuticals (VRTX): Biotech Beast Or Overhyped Bubble? - AD HOC NEWS
12 Best Future Stocks to Buy For the Long Term - Insider Monkey
The Truth About Vertex Pharma: Why Wall Street Can’t Stop Watching This Biotech Beast - AD HOC NEWS
Vertex Pharma Is Quietly Dominating – Is This Biotech Stock the Next Monster Win? - AD HOC NEWS
Growth Report: Can Vertex Pharmaceuticals Incorporated reach all time highs this year - baoquankhu1.vn
Implied Volatility Surging for Vertex Pharmaceuticals Stock Options - Yahoo Finance
Vertex Pharmaceuticals Incorporated $VRTX Shares Sold by TD Private Client Wealth LLC - MarketBeat
Country Trust Bank Increases Stock Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Here's what to expect from Vertex Pharmaceuticals' next earnings report - MSN
Vertex Pharmaceuticals (VRTX) Stock Sinks As Market Gains: Here's Why - Yahoo Finance
Stock Market Today, Jan. 15: ImmunityBio Surges After Anktiva Revenue Jumps 700% - The Motley Fool
Meritage Portfolio Management Decreases Stock Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Prediction: These Could Be the Best-Performing Healthcare Stocks Through 2030 - Finviz
Manning & Napier Advisors LLC Purchases 241,242 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals Incorporated $VRTX Shares Purchased by Nordea Investment Management AB - MarketBeat
What is Vertex Pharmaceuticals Incorporated s debt to equity ratio2025 Key Highlights & Risk Adjusted Swing Trade Ideas - bollywoodhelpline.com
Analysts Offer Insights on Healthcare Companies: Axsome Therapeutics (AXSM), Vertex Pharmaceuticals (VRTX) and CareDx (CDNA) - The Globe and Mail
Vertex Pharmaceuticals Targets Five Product Launches in Five Years Across Diverse Disease Areas - geneonline.com
JPM26: Vertex hopes to match cystic fibrosis success in pain and kidney disease - Pharmaceutical Technology
Here's What to Expect From Vertex Pharmaceuticals' Next Earnings Report - Yahoo Finance
Vertex Pharmaceuticals Inc (NASDAQ:VRTX) Emerges as a Prime GARP Investment Candidate - Chartmill
Sumitomo Mitsui Trust Group Inc. Acquires 45,623 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
VRTX: Strong growth in CF, pain, and renal, with five launches in five years and $12B revenue guidance - TradingView — Track All Markets
Bernstein Upgrades Vertex Pharmaceuticals (VRTX) - Nasdaq
How Is The Market Feeling About Vertex Pharmaceuticals Inc? - Benzinga
Bernstein upgrades Vertex ahead of key renal trial readouts By Investing.com - Investing.com India
Vertex Pharmaceuticals Inc Stock (VRTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.82%
0.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):